News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biotech Venture Fund's Portfolio Company, Infectex, Enrolls First Multi-Drug Resistant (MDR-TB) Patients in Pivotal Clinical Trial of SQ109, Licensed From Sequella, Inc.



12/19/2012 9:50:54 AM

MOSCOW & ROCKVILLE, Md.--(BUSINESS WIRE)--Infectex, a Russian biotech company in Maxwell Biotech Venture Fund’s portfolio, announced today enrollment of the first patients in its Phase IIb-III clinical trial of SQ109 for MDR-TB. Infectex was founded in 2011 to develop and commercialize innovative products for the treatment of TB. The study, which will be conducted at specialized clinical centers in Russia, is expected to continue for 2 years and will be the pivotal efficacy study in support of Russian and CIS regulatory approval. The trial will compare the effects of an optimized background drug regimen alone with an optimized background regimen plus SQ109 in MDR-TB patients. Study will be conducted in accordance with Russian and international treatment guidelines and in close partnership with U.S. biotech company Sequella, the original developer of the drug.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES